Transaction DateRecipientSharesTypePriceValue
1st September 2020Lp Bleichroeder250,000Open or private sale$1.68$420,000.00
21st August 2020Jon S Saxe30,000Open or private purchase$0.69$20,700.00
3rd June 2020Judy R Joice34,864Exercise of derivative$0.78$27,193.92
3rd June 2020Judy R Joice22,956Open or private sale$2.45$56,283.52
3rd June 2020Judy R Joice22,956Exercise of derivative$0.78$17,905.68
3rd June 2020Judy R Joice34,864Open or private sale$2.45$85,479.56
26th May 2020Lp Bleichroeder39,388Open or private sale$2.50$98,525.14
27th March 2020Lp Bleichroeder10,325Open or private sale$4.09$42,199.31
26th March 2020Lp Bleichroeder17,175Open or private sale$4.40$75,540.80
18th March 2020Lp Bleichroeder34,066Open or private purchase$2.34$79,785.98
Durect logo

DURECT Corp. engages in the research, development, and manufacturing of pharmaceutical products. The company products include alzet and lactel. Its pipeline includes DUR-928, which focuses on lipid homeostasis, inflammation, and cell survival; and POSIMIR, which is an analgesic product intended to deliver bupivacaine.

Ticker: DRRX
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1082038
Employees: 90
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $18 M (-47%)
Inventory, Net: $3 M (0%)
Assets, Current: $60 M (-16%)
Property, Plant and Equipment, Net: $476 Th (1%)
Other Assets, Noncurrent: $283 Th (-74%)
Assets: $73 M (-15%)
Accounts Payable, Current: $2 M (-4%)
Accrued Liabilities, Current: $4 M (-41%)
Liabilities, Current: $10 M (-71%)
Long-term Debt, Excluding Current Maturities: $21 M (0%)
Other Liabilities, Noncurrent: $891 Th (11%)
Common Stock, Value, Issued: $19 Th (0%)
Additional Paid in Capital, Common Stock: $521 M (1%)
Retained Earnings (Accumulated Deficit): $485 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $71 Th (2266%)
Stockholders' Equity (Parent): $36 M (0%)
Liabilities and Equity: $73 M (-15%)
Revenue: $26 M (0%)
Cost of Revenue: $964 Th (-56%)
Research and Development: $7 M (-53%)
Operating Income/Loss: $15 M (187%)
Other Income, net: $417 Th (-44%)
EPS (basic): $0.07 (0%)
EPS (diluted): $0.07 (0%)